Health

SHERIDAN, WYOMING – November 9, 2024 – Canon Medical Systems USA, Inc., a leading provider of diagnostic imaging systems and healthcare IT solutions, announced today its participation in the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, Illinois, from December 1-5.

SHERIDAN, WYOMING – November 09, 2024-Enhancing EUV Lithography Materials Production in Japan and South Korea In a move set to revolutionize semiconductor manufacturing, FUJIFILM Corporation has announced the launch of its cutting-edge negative-tone resists and developer for EUV lithography.

SHERIDAN, WYOMING – NOVEMBER 09, 2024 – FUJIFILM Holdings Corporation is pleased to announce that Kenji Sukeno, Chairman, Director & Board Chairman, has been awarded the prestigious Order of the Rising Sun, Gold and Silver Star. This distinguished honor, bestowed by the Japanese government, recognizes individuals who have made significant contributions to the nation and the public good.

SHERIDAN, WYOMING – NOVEMBER 09, 2024 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, vaccines, advanced therapies, and oncolytic viruses, has announced the completion of the first phase of its expansion project at its Hillerød, Denmark site. This achievement is a signifi

SHERIDAN, WYOMING – November 09, 2024-Company Maintains Positive Outlook for the Remainder of the Fiscal Year FUJIFILM Holdings Corporation today announced strong financial results for the first half of the fiscal year ending March 31, 2025. The company reported a 9.1% year-over-year increase in revenue, reaching JPY1,514.7 billion. This growth was primar

SHERIDAN, WYOMING – November 09, 2024 – Varian Medical Systems, a Siemens Healthineers company, is proud to showcase its innovative TrueBeam® radiotherapy system, a cutting-edge technology designed to revolutionize cancer treatment. TrueBeam integrates hardware, software, treatment regimens, and safety features to provide clinicians with the tools they need to deliver precise and effective radiation therapy.

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc. New Leadership Appointments Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company. Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.

SHERIDAN, WYOMING – November 09, 2024– In a move set to transform blood processing in the United States, Terumo Blood and Cell Technologies (Terumo BCT) has launched the Reveos™ Automated Blood Processing System. This innovative technology, already used in over 50 countries for more than a decade, promises to significantly enhance efficiency and address critical platelet shortages. "Reveos is a revolutionary technology that automates whole blood processing. By streamlining the process, it significantly improves efficiency and consistency compared to traditional manual methods used by U.S. blood centers," says Chetan Makam, General Manager, Global Blood Solutions, Terumo BCT. "It's a new way to be more efficient for blood centers, for processing whole blood into its components including platelets. Reveos will help blood centers do more with the blood donors already walking through the doors."

SHERIDAN, WYOMING – November 09, 2024-Terumo Corporation, a leading medical technology company, has raised its financial forecast for the fiscal year ending March 31, 2025. This comes on the heels of impressive first-half results and favorable shifts in foreign exchange rates. The company now anticipates consolidated revenue of 1.01 trillion yen, a 30 billion yen increase from its previous estimate. This upward revision reflects better-than-expected revenue in the first and second quarters, coupled with the yen's depreciation exceeding initial projections.

SHERIDAN, WYOMING – November 09, 2024 – Novartis, a global healthcare company, recently released promising data on its Kesimpta® (ofatumumab) treatment for relapsing multiple sclerosis (RMS). The findings, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting, highlight the long-term benefits of Kesimpta for both first-line and switch patients. Relapsing multiple sclerosis is a chronic disease that affects the central nervous system, disrupting the flow of information within the brain, and between the brain and body. It is characterized by periods of relapse (disease activity) and remission (recovery). Kesimpta is a targeted B-cell therapy that works by reducing the number of B-cells, a type of immune cell thought to play a key role in MS attacks.